HIV/AIDS Update - Prezista label update includes 192-week safety, resistance and efficacy data

Updates to the Prezista (darunavir) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on October 19, 2011 to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, “A randomized, controlled, open-label Phase 3 trial comparing PREZISTA/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects.”


In addition section 5.3 Severe Skin Reactions now includes the following text about PREZISTA/ritonavir + raltegravir containing regimens.

Rash occurred more commonly in treatment-experienced subjects receiving regimens containing PREZISTA/ritonavir + raltegravir compared to subjects receiving PREZISTA/ritonavir without raltegravir or raltegravir without PREZISTA/ritonavir. However, rash that was considered drug related occurred at similar rates for all three groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash.

The complete revised label will be posted soon at Drugs@FDA .

Richard Klein

Office of Special Health Issues

Food and Drug Administration

Kimberly Struble

Division of Antiviral Drug Products

Food and Drug Administration

If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDA Patient Network News, a twice monthly newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients and patient advocates.
https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_203